Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Biogen logo

Biogen Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Biogen holds $29.5B in total assets. Shareholders' equity is $18.7B against $6.6B in total debt. Cash and equivalents total $3.4B. The current ratio is 3.06 and debt-to-equity is 0.352. Based on the Q1 2026 filing.

Total Assets$29.5BTotal Stockholders Equity$18.7BLong Term Debt$6.3BCash And Equivalents$3.4BTotal Current Assets$9.2BTotal Current Liabilities$3.0B
Latest FilingQ1 2026
Report Date2026-04-29
Market Cap$29.5B
P/E Ratio20.78
ROE7.98%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$424.2M$391.5M$408.4M$413.1M$432M$358.5M
Accrued expenses$2.8B$192.3M$260.9M$310.7M$2.8B$2.5B
Derivative Liability, Current————$56.7M$38.2M
Other accrued liabilities$2.8B$2.5B$2.7B$2.8B$2.8B$2.5B
Derivative Liabilities - Fair Value————$56.7M$38.2M
Income taxes payable$548.3M$626.1M$114.8M$103.3M$114.8M$93.6M
Total current liabilities$5.5B$5.3B$3.2B$3.3B$3.3B$3B

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accumulated Goodwill Impairment Losses—$0$0$0—$0
Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years)————$419.3M$455.9M
Deferred tax assets$190.5M$133.2M$118.3M$358.1M$507.6M$483.5M
Deferred Tax Assets and Other Non-Current Assets$560.5M$559.1M$637.7M$729.7M$750.6M$777.5M
Equity Amortized Cost$668.7M$668.7M$668.7M$227.8M$227.7M$227.8M
Available-for-sale securities$0$668.7M$668.7M$227.8M$419.5M$454.7M
Total investment securities————$118.1M$137.4M
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)—$665M$665M$580M—$650M
Finite Lived Intangible Assets - Gross$14.1B$14.1B$14.1B$14.1B$14.1B$14.1B
Goodwill$6.5B$6.5B$6.5B$6.5B$6.5B$6.5B
Equity securities$179.7M$146.9M$157M$103.9M$118.1M$137.4M
Intangible Assets Gross (Excluding Goodwill)$15.9B$15.9B$15.9B$15.9B$15.9B$15.9B
Intangible assets, net$9.7B$7.8B$7.7B$7.5B$7.4B$7.3B
Investments - Amortized Cost Basis———$97.6M$1.2B$1.4B
Net Investment in Lease$356.4M$346.4M$334.5M$330.5M$265.4M$251.3M
Long-term marketable securities$0———$431.9M$465.6M
Deferred tax assets$324.2M$307.5M$330.9M$312.4M$292.5M$238.2M
Intangible assets — net$7.9B$7.8B$7.7B$7.5B$7.4B$7.3B
Other intangible assets—net$9.7B$9.6B$9.5B$9.3B$9.2B$9.1B
Operating lease right-of-use assets$356.4M$346.4M$334.5M$330.5M$265.4M$251.3M
Other non-current assets$560.5M$559.1M$637.7M$729.7M$750.6M$777.5M
Operating lease right-of-use assets$356.4M$346.4M$334.5M$330.5M$265.4M$251.3M
Operating Lease Right-of-Use Assets in Other Assets$356.4M$346.4M$334.5M$330.5M$265.4M$251.3M
Other non-current assets$560.5M$559.1M$637.7M$729.7M$750.6M$777.5M
Accumulated depreciation$2.7B$2.7B$2.8B$2.9B$2.9B$3B
Property and equipment, net$3.2B$3.1B$3.1B$3.1B$3.1B$3B
Software and Technology Licenses, Net$560.5M$559.1M$637.7M$729.7M$750.6M$777.5M
Total assets$28B$28B$28.3B$29.2B$29.4B$29.5B

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Additional paid-in capital$569.4M$629.9M$714M$797.7M$863.1M$896.7M
Accumulated other comprehensive income (loss)-$136.2M-$174.5M-$238.1M-$214.8M-$182M-$140.2M
Common stock$100K$100K$100K$100K$100K$100K
Common Stock Par Value Per Share—$0.00$0.00$0.00—$0.00
Cumulative Gross Losses and Impairments—$0$0$0—$0
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively$100K$100K$100K$100K$100K$100K
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0$0$0$0$0$0
Treasury Stock, Value$3B$3B$3B$3B$3B$3B
Preferred stock$0$0$0$0$0$0
Preferred Stock Par Value Per Share—$0.00$0.00$0.00—$0.00
Retained earnings$19.3B$19.5B$20.1B$20.6B$20.6B$20.9B
Total liabilities and stockholders' equity$28B$28B$28.3B$29.2B$29.4B$29.5B
Total stockholders' equity$16.7B$17B$17.6B$18.2B$18.3B$18.7B
Treasury stock$3B$3B$3B$3B$3B$3B
Unrealized Gains on Investments———$0$200K$0
Unrealized Losses on Investments (Before Tax)———$0$0$2M

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Available-for-Sale Debt Securities - Amortized Cost———$97.6M$807.2M$900.8M
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)———$97.6M$807.2M$900.8M
Available-for-Sale Debt Securities - Fair Value by Maturity———$97.6M$1.2B$1.4B
Available-for-Sale Debt Securities - Single Maturity Date———$97.6M$1.2B$1.4B
Allowance for Doubtful Accounts$3.1M$2.2M$2.2M$2.2M$3M$3M
Allowance for Doubtful Accounts Receivable (Current)$3.1M$2.2M$2.2M$2.2M$3M$3M
Cash and cash equivalents$2.4B$2.6B$2.8B$3.9B$3B$3.4B
Cash, Cash Equivalents, and Marketable Securities———$97.6M$1.2B$1.4B
Available For Sale Securities Debt Securities Current$0——$97.6M$807.2M$900M
Derivatives————$10M$19.1M
Due from unconsolidated joint business$464M———$524.6M—
Finished goods$353.8M$367.9M$478M$440.5M$424.9M$458.2M
Other current assets$752.5M$757.3M$850.6M$916.8M$1.1B$1.2B
Current Equity Amortized Cost$668.7M$668.7M$668.7M$227.8M$227.7M$227.8M
Derivative Assets, Current————$10M$19.1M
Equity Securities (FV-NI) - Cost Basis$668.7M$668.7M$668.7M$227.8M$227.7M$227.8M
Derivative assets————$400K$5.9M
Trading assets———$97.6M$807.2M$900M
Income taxes receivable————$693.6M$661.6M
Finished goods$353.8M$367.9M$478M$440.5M$424.9M$458.2M
Raw materials$317.8M$306.4M$305M$296.2M$293.4M$278.7M
Work in process$1.9B$1.7B$1.6B$1.6B$1.6B$1.4B
Inventories$93.9M$117.4M$150.6M$162.3M$145.4M$139.5M
Prepaid expenses and other current assets$752.5M$757.3M$850.6M$916.8M$1.1B$1.2B
Short-term investments$0——$97.6M$807.2M$900M
Total current assets$7.5B$7.6B$8B$8.9B$9B$9.2B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
AOCI - Cash Flow Hedge Reclassification (Next 12 Months)—$13.4M$111.1M$90.8M—$16.4M
Cumulative Cost Basis$668.7M$668.7M$668.7M$97.6M$1.2B$1.4B
Fair Value Measurement Disclosure$512.8M$522.4M$534.9M$391.2M$246.4M$266.9M
Income taxes payable – long-term$156.7M$162.1M$165.1M$164.7M$166.4M$174.2M
Allowance for doubtful accounts$3.1M$2.2M$2.2M$2.2M$3M$3M
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax———$0$0$2M
Gross Unrealized Gains———$0$200K$0
Total———$97.6M$1.2B$1.4B
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five————$419.3M$455.9M
Due after five years————$12.4M$10.9M
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five————$419.5M$454.7M
Due after five years————$12.4M$10.9M
Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost———$97.6M$1.2B$1.4B
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One———$97.6M$807.2M$900.8M
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One———$97.6M$807.2M$900M
Available for sale investments———$97.6M$1.2B$1.4B
Common stock, par value (in dollars per share)—$0$0$0—$0
Deferred income taxes$190.5M$133.2M$118.3M$358.1M$507.6M$483.5M
Derivative Liability, Noncurrent————$2.2M—
Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax$489M$521.8M$511.7M$123.9M$109.6M$90.4M
Gross Unrealized Gains$0$0$0$0$0$0
Cost$668.7M$668.7M$668.7M$227.8M$227.7M$227.8M
Finite-Lived Intangible Assets, Accumulated Amortization$6.3B$6.3B$6.4B$6.6B$6.7B$6.8B
2028—$600M$600M$490M—$525M
2030—$665M$665M$580M—$650M
2031—$700M$700M$650M—$700M
Remainder of 2026—$350M$240M$130M—$400M
2027—$560M$565M$485M—$485M
2029—$630M$630M$525M—$575M
Gross Carrying Amount$14.1B$14.1B$14.1B$14.1B$14.1B$14.1B
Foreign currency cash flow hedge gain (loss) to be reclassified during next 15 months—$14.1M$135.2M$103.4M—$14.7M
Goodwill accumulated impairment losses—$0$0$0—$0
Indefinite- lived intangible impairment$15.9B$15.9B$15.9B$15.9B$15.9B$15.9B
Inventory, Net Current and Noncurrent$2.6B$2.4B$2.4B$2.4B$2.3B$2.1B
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities$23.6M$19.3M$49.3M$44.8M$49.8M$48.4M
Investments Fair Value Disclosure————$118.1M$137.4M
Long Term Notes Payable$4.5B———$6.3B—
Plan Assets For Deferred Compensation Fair Value Disclosure————$52.2M$56.8M
Preferred Stock, Par or Stated Value Per Share—$0$0$0—$0
Share of net profit from sage therapeutics, Percent—50.0%50.0%50.0%—50.0%
Valuation Allowances And Reserves Balance$1.1B$1.2B$1.3B$1.3B$1.2B$1.2B
Remainder of Fiscal Year 2024—$350M$240M$130M—$400M
Remainder of Fiscal Year 2025—$350M$240M$130M—$400M

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Contingent Consideration Liability (Non-Current)$221.6M$228.1M$237.7M$242.6M$246.4M$266.9M
Derivative Liabilities (Non-Current)————$2.2M—
Long-term debt$4.5B$4.5B$6.3B$6.3B$6.3B$6.3B
Long-Term Debt - Fair Value$5.4B$5.5B$5.6B$5.7B$5.7B$5.6B
Notes Payable - Fair Value$5.4B$5.5B$5.6B$5.7B$35M$35M
Operating lease liabilities, non-current$334.5M$323.4M$310.9M$305M$290.4M$273.4M
Other non-current liabilities$732.3M$751.7M$799.6M$761.8M$748.5M$787.1M
Senior unsecured notes, net$6.3B$6.3B$6.3B$6.3B$6.3B$6.3B
Total liabilities$11.3B$11.1B$10.7B$11B$305.3M$305.1M